Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
P2Y12 antagonism: promises and challenges Michelson ADArterioscler Thromb Vasc Biol 2008[Mar]; 28 (3): s33-8The P2Y12 antagonist clopidogrel has a well-established role as an antithrombotic agent in the settings of percutaneous coronary intervention and acute coronary syndromes. However, several challenges remain, including the relatively slow onset of action of clopidogrel and the phenomenon of clopidogrel response variability or "resistance". Novel P2Y12 antagonists, including prasugrel, AZD6140, and cangrelor, have a faster onset of action, as well as more potent, and less variable, inhibition of platelet function ex vivo. Whether this promise will be translated into clinical benefit for patients will be determined by the results of ongoing phase 3 clinical trials.|*Purinergic P2 Receptor Antagonists[MESH]|Acute Coronary Syndrome/diagnosis/*drug therapy/*mortality/therapy[MESH]|Angioplasty, Balloon, Coronary[MESH]|Clinical Trials, Phase III as Topic[MESH]|Clopidogrel[MESH]|Dose-Response Relationship, Drug[MESH]|Drug Administration Schedule[MESH]|Drug Resistance[MESH]|Education, Medical, Continuing[MESH]|Female[MESH]|Humans[MESH]|Male[MESH]|Maximum Tolerated Dose[MESH]|Membrane Proteins/*antagonists & inhibitors[MESH]|Platelet Aggregation Inhibitors/*administration & dosage/adverse effects[MESH]|Platelet Aggregation/drug effects[MESH]|Prognosis[MESH]|Randomized Controlled Trials as Topic[MESH]|Receptors, Purinergic P2Y12[MESH]|Risk Assessment[MESH]|Survival Analysis[MESH]|Ticlopidine/administration & dosage/adverse effects/*analogs & derivatives[MESH]|Treatment Outcome[MESH] |
